Alex De Crespigny
Overview
Explore the profile of Alex De Crespigny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torkaman M, Jemaa S, Fredrickson J, Fernandez Coimbra A, De Crespigny A, Carano R
BMC Med Imaging
. 2025 Feb;
25(1):52.
PMID: 39962481
Background: 18-Fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is a valuable imaging tool widely used in the management of cancer patients. Deep learning models excel at segmenting highly metabolic tumors but...
2.
Jemaa S, Ounadjela S, Wang X, El-Galaly T, Kostakoglu L, Knapp A, et al.
J Clin Oncol
. 2024 Jun;
42(25):2966-2977.
PMID: 38843483
Purpose: Artificial intelligence can reduce the time used by physicians on radiological assessments. For F-fluorodeoxyglucose-avid lymphomas, obtaining complete metabolic response (CMR) by end of treatment is prognostic. Methods: Here, we...
3.
Zou Y, Hou X, Anegondi N, Negahdar M, Cheung D, Belloni P, et al.
ERJ Open Res
. 2023 Oct;
9(5).
PMID: 37868144
Background: Identifying systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF) patients at risk of more rapid forced vital capacity (FVC) decline could improve trial design. The purpose of the present...
4.
Krishnan A, Song Z, Clayton D, Jia X, De Crespigny A, Carano R
Sci Rep
. 2023 Mar;
13(1):4102.
PMID: 36914715
T2 lesion quantification plays a crucial role in monitoring disease progression and evaluating treatment response in multiple sclerosis (MS). We developed a 3D, multi-arm U-Net for T2 lesion segmentation, which...
5.
Ogasawara A, Kiefer J, Gill H, Chiang E, Sriraman S, Ferl G, et al.
Eur J Nucl Med Mol Imaging
. 2022 Nov;
50(2):631.
PMID: 36427067
No abstract available.
6.
Ogasawara A, Kiefer J, Gill H, Chiang E, Sriraman S, Ferl G, et al.
Eur J Nucl Med Mol Imaging
. 2022 Oct;
50(2):287-301.
PMID: 36271158
Background: ZED8 is a novel monovalent antibody labeled with zirconium-89 for the molecular imaging of CD8. This work describes nonclinical studies performed in part to provide rationale for and to...
7.
Coimbra A, Rimola J, Cuatrecasas M, De Hertogh G, Van Assche G, Vanslembrouck R, et al.
Clin Transl Gastroenterol
. 2022 Jul;
13(7):e00505.
PMID: 35905415
Introduction: Magnetic resonance enterography (MRE) is useful for detecting bowel strictures, whereas a number of imaging biomarkers may reflect severity of fibrosis burden in Crohn's disease (CD). This study aimed...
8.
Wang X, Jemaa S, Fredrickson J, Fernandez Coimbra A, Nielsen T, De Crespigny A, et al.
BMC Med Imaging
. 2022 Mar;
22(1):58.
PMID: 35354384
Purpose: Positron emission tomography (PET)/ computed tomography (CT) has been extensively used to quantify metabolically active tumors in various oncology indications. However, FDG-PET/CT often encounters false positives in tumor detection...
9.
Song Z, Krishnan A, Gaetano L, Tustison N, Clayton D, De Crespigny A, et al.
Neuroimage Clin
. 2022 Feb;
34:102959.
PMID: 35189455
Background: Despite advancements in treatments for multiple sclerosis, insidious disease progression remains an area of unmet medical need, for which atrophy-based biomarkers may help better characterize the progressive biology. Methods:...
10.
Krishnan A, Song Z, Clayton D, Gaetano L, Jia X, De Crespigny A, et al.
Radiology
. 2021 Dec;
302(3):662-673.
PMID: 34904871
Background Deep learning-based segmentation could facilitate rapid and reproducible T1 lesion load assessments, which is crucial for disease management in multiple sclerosis (MS). T1 unenhancing and contrast-enhancing lesions in MS...